The Biomedical Division of PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura; hereafter referred to as "PHCbi"), a subsidiary of PHC Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo, hereafter referred to as "PHCHD") announces it has signed an exclusive agreement with MaxCyte, Inc. to distribute the MaxCyte ExPERT platform(*1) in Japan.
ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, announced the first patient treatments using its ZAP-X® Gyroscopic Radiosurgery® platform in Latin America. Located in Neuland, Boquerón, Paraguay, Radioterapia Concordia (www.saludconcordia.com) has officially commenced clinical use, marking a major milestone in the decentralization of state-of-the-art brain tumor care across the region.
World Precision Instruments (WPI), a global leader in transepithelial electrical resistance (TEER) instrumentation, and SynVivo Inc., a pioneer in Organ-on-a-Chip (OOC) technology, announced the commercial launch of a next-generation multiplexed TEER-on-a-Chip platform—a breakthrough solution enabling real-time, high-throughput measurement of barrier integrity in advanced Organ-on-a-Chip models.
Somnics Health, a pioneer in next-generation sleep apnea solutions, announces the launch of iNAP Essentials, a breakthrough program giving patients access to iNAP Sleep Therapy for just $58/month over 24 months. This new initiative removes one of the biggest barriers to treatment—cost—and expands access to comfortable, mask-free therapy for patients with Obstructive Sleep Apnea (OSA).
HistoSonics, the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, announced that Addenbrookes Hospital of Cambridge University Hospital Foundation and Trust will be the first site in the United Kingdom and European continent to offer histotripsy to both NHS and private patients. This was made possible through a generous donation by the Li Ka Shing Foundation (LKSF) as well as the expedited limited market access granted by the MHRA in April 2025.
ZAP Surgical Systems, Inc., a global leader in non-invasive robotic brain surgery, announced that its first ZAP-X® Gyroscopic Radiosurgery® platform will soon be installed in Mexico at the newly established Gray Medical Institute, located in San Pedro, part of the Monterrey Metropolitan area in the Mexican state of Nuevo León.
Hyperfine, Inc. the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—announced FDA clearance of its most significant technological advancement to date. The clearance includes an entirely new portable MRI scanner powered by the proprietary Optive AI™ software.
GE HealthCare announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for clinicians now recommend considering fluoroestradiol (FES) positron emission tomography (PET) for systemic staging in patients with recurrent or metastatic lobular breast cancer.
Atia Vision, Inc., a Shifamed portfolio company, announced it has received Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) to begin a traditional feasibility clinical study of its OmniVu™ Lens System. This novel intraocular lens is designed to restore dynamic range of vision following cataract surgery, going beyond the capabilities of current presbyopia-correcting lenses.
Stryker a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting† vertebrogenic pain relief1.